Recent Company News

• 09:58 PM ET Feb 09, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 04:53 PM ET Feb 09, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:50 AM ET Feb 09, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:46 AM ET Feb 09, 2026
  

  Innovent Biologics initiated overweight at Northeast Securities

• 05:51 AM ET Feb 09, 2026
  

  StreetAccount Macro Headlines:

• 05:42 AM ET Feb 08, 2026
  

  Innovent Biologics partners with Eli Lilly to develop new medicines in oncology and immunology for $350M upfront payment (HK$79.50, 0.00)

• 01:16 AM ET Feb 05, 2026
  

  Street Takeaways - Innovent Biologics Q4/FY product sales (HK$78.65, -2.00)

• 05:29 AM ET Feb 04, 2026
  

  Innovent Biologics reports Q4 product revenue of more than CNY3.3B, +60% y/y (HK$80.65, 0.00)

• 01:03 AM ET Feb 04, 2026
  

  StreetAccount Sector Summary - China Healthcare January Recap

• 07:13 PM ET Jan 26, 2026
  

  Innovent Biologics.anti-GPRC5D/BCMA/CD3 tri-specific IBI3003 granted FDA Fast Track for R/R multiple myeloma (HK$81.65, 0.00)